Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026)
Harvard Bioscience's (HBIO) quarterly EBITDA Margin came in at 4.3% in Q2 2026, down 30.0% year-over-year from 6.15% in Q2 2025, and up 23.92% quarter-over-quarter from 5.66% in Q1 2026.
Powered by 
Analysis
Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported EBITDA Margin for 17 consecutive years, with 4.3% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 30.0% year-over-year to 4.3% in Q2 2026; TTM through Jun 2026 was 0.28%, a 5871.0% increase from a year earlier, with the FY2025 full-year figure at 56.13%, down 4953.0% from the prior year.
- EBITDA Margin was 4.3% for Q2 2026 at Harvard Bioscience, up from 5.66% in the prior quarter.
- Over five years, EBITDA Margin peaked at 13.69% in Q2 2022 and troughed at 228.11% in Q1 2025.
- A 5-year average of 15.55% and a median of 3.84% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 21881 bps in 2025 and surged 22245 bps in 2026, its largest moves.
- Over 5 years, EBITDA Margin stood at 1.61% in 2022, then soared by 162 bps to 1.0% in 2023, then slumped by 96 bps to 0.04% in 2024, then jumped by 15983 bps to 7.2% in 2025, then sank by 160 bps to 4.3% in 2026.
- The last three EBITDA Margin figures came in at 4.3% (Q2 2026), 5.66% (Q1 2026), and 7.2% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 224.04 Bn | 219.98 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 142.34 Bn | 137.99 Bn | 3.61 Bn | 17.99% |
| 3 | Agilent Technologies | 40.26 Bn | 38.50 Bn | 1.04 Bn | 23.64% |
| 4 | Illumina | 30.64 Bn | 29.47 Bn | 770.00 Mn | 21.14% |
| 5 | Revvity | 13.61 Bn | 12.59 Bn | 416.87 Mn | 12.24% |
| 6 | Bio-Techne | 11.27 Bn | 11.00 Bn | 211.39 Mn | 23.13% |
| 7 | Bio-Rad Laboratories | 9.94 Bn | 8.32 Bn | 345.80 Mn | 11.15% |
| 8 | Repligen | 9.18 Bn | 8.17 Bn | 110.04 Mn | 6.85% |
| 9 | 10x Genomics | 8.69 Bn | 8.14 Bn | 112.50 Mn | -12.95% |
| 10 | Harvard Bioscience | 35.61 Mn | 29.11 Mn | 12.63 Mn | -4.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.30% |
| Mar 31, 2026 | -5.66% |
| Dec 31, 2025 | 7.20% |
| Sep 30, 2025 | 0.96% |
| Jun 30, 2025 | -4.00% |
| Mar 31, 2025 | -228.11% |
| Dec 31, 2024 | 0.04% |
| Sep 30, 2024 | -8.53% |
| Jun 30, 2024 | -8.96% |
| Mar 31, 2024 | -9.30% |
| Dec 31, 2023 | 1.00% |
| Sep 30, 2023 | -3.68% |
| Jun 30, 2023 | 2.77% |
| Mar 31, 2023 | 5.83% |
| Dec 31, 2022 | -1.61% |
| Sep 30, 2022 | -13.97% |
| Jun 30, 2022 | 13.69% |
| Mar 31, 2022 | -23.32% |
| Dec 31, 2021 | 5.14% |
| Sep 30, 2021 | 1.85% |